Reality Check on Kidney Cancer
Market access for kidney cancer treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, about 58% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: In June 2019, the FDA approved Pfizer's Zirabev, a biosimilar to Roche's blockbuster cancer treatment Avastin for the treatment of kidney, ovarian and colorectal cancer
- Key Findings: Currently, Sutent leads the renal cell carcinoma market and may have bolstered its standing with 2017’s label expansion to include use in the adjuvant setting
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.